Diabetes Research Articles

Antidiabetic Activity Test of Fe(III) Complex Compound with Arginine Ligand in Male Mice (Mus Musculus L.)

Diabetes mellitus is characterized by high blood sugar levels in the body. Treatment for type 1 diabetes mellitus is with insulin injections while treatment for type 2 diabetes mellitus generally uses oral medication. Currently, people are looking for diabetes drugs made from complex compounds using metals. The development of research and utilization of Fe(III) complex compounds is still limited, thus, in this study the synthesis of Fe(III) complex compounds with arginine ligands was carried out. The results of the research obtained a complex compound of Fe(III)-arginine with 96%, in the form of a brown gel with a sample weight of 0.5601 g. Characterization using a UV-Vis spectrophotometer showed absorption at a wavelength of 203 nm which indicated the absorption of the Fe(III)-arginine complex. The results of FTIR analysis showed a typical absorption of Fe–O and Fe–N bonds at a wavelength of 500–600 nm. The results of the calculation of the mice's body weight decreased when induced by alloxan. After 3 and 4 weeks, the mice's body weight returned to stability. The highest decrease in glucose levels was in dose 2, namely 100 μg/kg bw with a decrease in %GL of 66.72%. The results of this study show that the complex compound Fe(III) arginine can reduce blood glucose levels in mice.

Association of the triglyceride glucose index with acute renal failure in diabetes mellitus: a cross-sectional study based on participants from the MIMIC-iv database

Association of the triglyceride glucose index with acute renal failure in diabetes mellitus: a cross-sectional study based on participants from the MIMIC-iv database

Study the role of xanthine oxidase inhibitor, allopurinol in experimentally induced steatohepatitis

Nonalcoholic steatohepatitis (NASH) is a chronic liver disease which can lead to cirrhosis and hepatic failure. It is observed in patients with both type 1 and type 2 diabetes mellitus (T1DM, T2DM). Allopurinol, a xanthine oxidase inhibitor that is widely used in clinical practice, has been demonstrated to reduce hepatic oxidative stress and attenuate acute liver injury which may be through activation of antioxidant pathways. This work aimed at investigating the role of Allopurinol (ALP) in attenuation of type 1 diabetes associated with Nonalcoholic fatty liver disease (NAFLD) and exploring the possible molecular mechanism by which ALP attenuates NASH in type 1 diabetes. Forty-five adult male albino rats were included in the study. They were randomly allocated to 3 equal groups: group I (control), Group II (diabetic animals), Group III (diabetic animals with allopurinol treatment). At the end of this experimental study measurements of serum glucose, ALT, AST, cholesterol, triglyceride, serum levels of uric acid, malondialdehyde (MDA), serum superoxide dismutase (SOD) were done. Histological analysis of liver tissue to diagnose steatohepatitis and gene expression of nuclear factor-erythroid-2- related factor-2 (Nrf2) & TNFα were done. Diabetic rates treated with allopurinol (group III) showed decrease in serum levels of ALT, AST, cholesterol, uric acid and MDA compared to diabetic rat group. As regards TNF, gene expression was significantly decreased in group III compared to group II. This study also demonstrated that Nrf2α was significantly increased in group III compared to group II. Allopurinol also, ameliorated the histopathological changes observed in group II. In conclusion, allopurinol treatment increases the Nrf2 gene expression in the liver of STZ-induced diabetic rats and ameliorates steatohepatitis through modulation of TNF-α gene expression. Allopurinol could be a candidate for prevention or treatment of NAFLD.

Gender‐specific genetic influence of rs1111875 on diabetes risk: Insights from the Taiwan biobank study

ABSTRACTBackgroundThis study investigates the gender‐specific genetic influence of the single nucleotide polymorphism (SNP) rs1111875 on diabetes risk within the Taiwanese population using data from the Taiwan Biobank. Diabetes mellitus, particularly type 2 diabetes (T2D), is influenced by genetic factors, and the rs1111875 SNP near the hematopoietically expressed homeobox (HHEX) gene has been linked to T2D susceptibility.MethodsThe study included 69,272 participants after excluding those from arsenic‐polluted areas and those with incomplete data. Logistic regression models were used for analyses.ResultsThe analyses revealed that the CT genotype of rs1111875 was associated with an increased risk of diabetes (OR = 1.092, 95% CI = 1.030–1.157, P = 0.003), as was the TT genotype (OR = 1.280, 95% CI = 1.165–1.407, P < 0.001). The effect was more pronounced in women (CT: OR = 1.118, 95% CI = 1.036–1.207, P = 0.004; TT: OR = 1.404, 95% CI = 1.243–1.585, P < 0.001). Men exhibited a higher overall risk of diabetes (OR = 1.565, 95% CI = 1.445–1.694, P < 0.001) and had a higher prevalence (12.71% vs 7.80%, P < 0.001) compared to women.ConclusionsThe findings underscore the importance of considering gender differences in genetic studies of diabetes and suggest that personalized diabetes management strategies should account for both genetic and gender‐specific risk factors. This research contributes to the broader understanding of genetic determinants of diabetes and their interaction with gender, aiming to enhance personalized healthcare strategies for diabetes prevention and treatment.

Characterisation of islet antibody‐negative type 1 diabetes mellitus in Indian children

AbstractAimsIslet antibody‐negative type 1 diabetes mellitus (T1DM) has not been well characterised. We determined the frequency of antibody‐negative T1DM and compared it with antibody‐positive T1DM in a cohort of north Indian children.MethodsIn a multi‐centre, prospective, observational study, 176 Indian children (age 1–18 years) were assessed within 2 weeks of diagnosis of T1DM. Antibodies against GAD65 (GADA), islet antigen‐2 (IA‐2A) and zinc transporter 8 (ZnT8A), were estimated using validated ELISA. HLA‐DRB1, DQA1 and DQB1 alleles were studied by Luminex‐based typing. Monogenic diabetes was determined by targeted next‐generation sequencing using the Illumina platform.ResultsAfter excluding 12 children with monogenic diabetes, GADA, IA‐2A and ZnT8A were present in 124 (76%), 60 (37%) and 62 (38%) o children, respectively, while 24 (15%) were negative for all antibodies. A single antibody (most frequently GADA) was present in 68 (41%) of children, while all three antibodies were found in 34 (21%). Islet antibody‐negative T1DM (n = 24, 15%) did not differ from antibody‐positive children in their clinical features, HbA1c or plasma C‐peptide, both at onset or after 1 year follow‐up (available in 62 children). The frequency of other organ‐specific antibodies or high‐risk HLA‐DR and DQ alleles were also similar. Children with a single islet antibody did not differ from those with multiple antibodies.ConclusionsThe frequency of various islet‐antibodies, in isolation and combination, differed considerably from studies among children of European descent with T1DM. Children with T1DM who were islet antibody‐negative were indistinguishable from those who were antibody‐positive.

Undiagnosed hypertension and diabetes mellitus in the Tabari cohort: a population-based study

Undiagnosed hypertension and diabetes mellitus in the Tabari cohort: a population-based study

Imbalance of Myoinositol and D‐Chiro‐Inositol in Saliva of Children With Type‐1 Diabetes Mellitus: A Cross‐Sectional Study

ABSTRACTObjectiveEarlier work suggests Myoinositol (MI) and D‐chiro‐ inositol (DCI) imbalance in urine and plasma of diabetic patients, and their potential for monitoring insulin resistance. This study aimed to assess levels of Myoinositol (MI) and D‐chiro‐ inositol (DCI) in saliva of children with type 1 diabetes mellitus (DM‐1) and controls, to verify if concentrations of MI and DCI are similarly altered in saliva, exploring their potential for monitoring DM‐1.Design, Patients and MeasurementsThis cross‐sectional clinical study enroled 45 patients (DM‐1, n = 25; Controls, n = 20). Children aged 3–12 years with fasting blood glucose levels > 126 mg/dL, and HbA1c levels > 7%. Saliva was collected, and salivary measurements included pH, flow rates and concentrations of MI, DCI and glucose, employing high‐performance liquid chromatography. Periodontal health was assessed using bleeding and plaque indices.ResultsChildren with DM‐1 showed elevated MI (p = 0.001), reduced DCI (p = 0.001), and increased MI‐DCI ratio (p = 0.001). The MI‐DCI ratio was elevated by 16‐fold among diabetic children. Plaque (p = 0.003) and gingival bleeding (p = 0.001) were higher in DM‐1 than controls. The MI increased the odds of an outcome of DM‐1 by 174%, while DCI reduced the odds by 63%, highlighting their strong and opposing effects on DM‐1.ConclusionsChildren with DM‐1 express higher MI and lower DCI levels, while non‐diabetic children show an inversion of these concentrations. Inositol imbalance in saliva of diabetic children resembles previous results in urine, and represents a possible venue for monitoring this disease, paving the way for future investigations into salivary inositols.

Investigating the mechanism of supraspinatus tendinopathy induced by type 2 diabetes mellitus in rats using untargeted metabolomics analysis

Investigating the mechanism of supraspinatus tendinopathy induced by type 2 diabetes mellitus in rats using untargeted metabolomics analysis

Deucravacitinib in Moderate to Severe Plaque Psoriasis: Comorbidities and Use of Prior and Concomitant Medication in Patients Enrolled in the Phase 3 POETYK PSO-1 and PSO-2 Trials

Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US, EU, and other countries for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy. Deucravacitinib was superior to placebo and apremilast in two global, phase 3 trials, POETYK PSO-1 (NCT03624127) and POETYK PSO-2 (NCT03611751), in moderate to severe plaque psoriasis. Here, we evaluate the comorbidities present at baseline and use of prior and concomitant medications in the pooled POETYK PSO-1 and PSO-2 trial populations to more comprehensively describe the medical history of individuals who participated in the deucravacitinib phase 3 trials. Methods: In POETYK PSO-1 and PSO-2, adults with moderate to severe plaque psoriasis were randomized 1:2:1 to oral placebo, deucravacitinib 6 mg once daily, or apremilast 30 mg twice daily. The rates of baseline comorbidities and medications received before and concomitantly with deucravacitinib in the pooled POETYK PSO trials were assessed. Medication classes evaluated included antidiabetic, antihypertensive and cardiovascular, lipid-reducing, anti-anxiety/depression, and oral contraceptive therapies. Results: Baseline patient demographics were similar across treatment arms. Metabolism and nutrition disorders were reported most often in each treatment arm (placebo, 42.7%; deucravacitinib, 39.2%; apremilast, 38.4%), followed by vascular disorders (33.7%, 34.9%, and 31.8%, respectively). Hypertension was the most common baseline medical condition (placebo, 30.3%, deucravacitinib, 32.8%, and apremilast, 29.1%), with obesity, hyperlipidemia, type 2 diabetes mellitus, and seasonal allergies each reported in 10% to 12% of patients in at least one treatment arm. Antihypertensive and cardiovascular agents, lipid-reducing agents, and antidiabetic agents were the most commonly reported medications. Conclusion: The phase 3 POETYK PSO trials enrolled adults with moderate to severe plaque psoriasis with a range of comorbidities consistent with the real-world population of patients with psoriasis. Medication classes used by patients were consistent with the comorbidities reported at baseline in both trials.

Is glucose‐induced hypersecretion of glicentin after the revision surgery using Roux‐en‐Y gastric bypass related to improved glycemic control due to insulin hypersecretion in a type 2 diabetes patient without diabetes remission after laparoscopic sleeve gastrectomy?

ABSTRACTWe report case details of a morbidly obese patient with type 2 diabetes mellitus (T2DM) who became a failure of diabetes remission after laparoscopic sleeve gastrectomy (LSG). He had a marked improvement of hyperglycemia after the revision surgery using Roux‐en‐Y gastric bypass (RYGB), where passage failure of a solid food intake at the gastric angle portion disappeared after the revision surgery. Interestingly, he showed improvements of insulin and a marked glicentin secretions with minor changes in glucagon related peptide 1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) secretions in the oral glucose tolerance test OGTT after the RYGB surgery compared with post‐LSG. Although a marked increase in glucose‐induced glicentin secretion after RYGB surgery with increased insulin secretion, further studies are needed to confirm if the increased glicentin secretion after RYGB surgery is linked to stimulation of insulin secretion.

The Influence of X Chromosome Parent-of-Origin on Glycemia in Individuals with Turner syndrome

Introduction: The cause of increased diabetes mellitus (DM) risk in individuals with Turner syndrome (TS) is poorly understood. Parent-of-origin effects related to whether the maternal or paternal X chromosome (Xchr) remains intact have been found for several TS phenotypes, including hypercholesterolemia. Therefore, Xchr parent-of-origin may impact DM risk in TS. The aim of this study was to determine whether Xchr parent-of-origin affects glycemia, as measured by oral glucose tolerance test (OGTT), in TS. Methods: A total of 81 individuals with 45,X karyotype from the TS: Genotype Phenotype study had Xchr parent-of-origin assessment and completed a 3-hour OGTT. Parallel-slopes multiple linear regression modeling was used to test whether Xchr parent-of-origin, age, and/or body mass index (BMI) significantly predicted incremental area under the glucose curve (iAUC). A second analysis included 62 additional individuals with 45,X mosaicism. Results: All three factors predicted iAUC glucose in the 81 individuals with 45,X karyotype (age: B = 0.36, p = 0.0004; BMI: B = 0.33, p = 0.001; Xchr parent-of-origin: B = 0.21; p = 0.01). The overall model remained statistically significant when including individuals with 45,X mosaicism, but Xchr parent-of-origin was no longer significant. Conclusions: Maternal Xchr monosomy predicts higher glucose concentration than paternal Xchr monosomy in response to oral glucose in 45,X individuals. This effect is obscured when including individuals who are mosaic, potentially due to the presence of both parent Xchrs in the non-45,X cell line.

Comparison of functional outcome after intracerebral hemorrhage in patients with or without end stage renal disease on hemodialysis: a propensity-score matched study

Abstract Background End stage renal disease (ESRD) requiring hemodialysis (HD) increases mortality among patients with intracerebral hemorrhage (ICH). The aim of this study is to investigate the clinical characteristics and outcome of ICH patients with ESRD on HD versus propensity-score matched controls. Methods This is a single center retrospective study. Consecutive ICH admissions at the University of California, Irvine Medical Center from January 1, 2018 to July 31, 2022 were analyzed. Results Among 347 ICH admissions that met inclusion criteria, 24 patients (6.92%) had ESRD on HD. Compared to patients without ESRD, patients with ESRD on HD had significantly higher rate of diabetes mellitus (79.2% vs. 36.8%, p < 0.01) and in-hospital mortality (25% vs. 7.43%, p < 0.01). There were no significant differences in demographics, other comorbidities, clinical characteristics, good (mRS score 0–3) or poor (mRS score 4–5) functional outcomes, rate of comfort care and the time to comfort care decision between the 2 groups. After propensity score matching, the ESRD group had a significantly higher in-hospital mortality rate (27.3% vs. 8%, p = 0.012) and a lower rate of obesity (9.1% vs. 34.1%, p = 0.02). Among patients who died during admission, ESRD on HD status did not inadvertently influence end-of-life care decisions. Univariate logistic regression and area under curve analysis showed that ICH score ≥ 3 was a predictor of increased mortality in both ESRD and non-ESRD groups. Conclusions ICH patients with ESRD on HD had significantly higher in-hospital mortality and lower rate of obesity than propensity score matched controls, suggesting a survival benefit from obesity. ICH score ≥ 3 is an independent predictor for poor outcomes in both ESRD and non-ESRD groups.

Impact of diabetes mellitus on the risk of Alzheimer’s disease: a mendelian randomization study

Impact of diabetes mellitus on the risk of Alzheimer’s disease: a mendelian randomization study

Dependent censoring bias assessment using inverse probability of censoring weights: Type 2 diabetes mellitus risk in patients initiating bisoprolol versus other antihypertensives in a Clinical Practice Research Datalink cohort study.

Dependent censoring involves a preferential attrition of a subgroup of interest; occurring in survival analysis, it may impact interpretation by introducing a selection bias. To assess the potential bias in a comparison of bisoprolol to other antihypertensives in terms of Type 2 diabetes mellitus (T2DM) incidence, inverse probability of censoring weights (IPCW) was used. It was further used to contextualize results obtained through competing risks analysis. Two estimands were considered to assess T2DM incidence while accounting for deviations from the initial antihypertensive monotherapy (DFM). A hypothetical estimand using IPCW, treating DFM as censoring, was interpreted together with a 'while-on-treatment' estimand, treating DFM as a competing risk. We illustrated our application with a cohort study based on Clinical Practice Research Datalink (CPRD) including 267,352 patients with newly diagnosed arterial hypertension between 2000 and 2017, initiating antihypertensive monotherapy among bisoprolol, other beta-blockers, renin-angiotensin system drugs (ACEi/ARB), diuretics and calcium-channel blockers. A mild dependent censoring process was hypothesized, leading to slight overestimation of T2DM incidence. Although subject to some limitations, a nonsignificant trend toward an excess of risk associated with ACEi/ARB was yielded consistently by IPCW and competing risks analyses. Conversely, in comparisons of bisoprolol versus either diuretics, other beta-blockers or calcium channel blockers, no significant differences or critical dependent censoring impact were found. Concurrent use of complementary estimands allowed formulating a refined interpretation of our findings: though not significant, the trend toward an excess of T2DM risk associated with a ACEi/ARB monotherapy compared with bisoprolol is likely not originating only from the minor dependent censoring. Reassessing identical estimands in other cohorts would provide insights to corroborate or refute this result.

Factors Affecting Mother‐Infant Bonding in Women with Gestational Diabetes Mellitus: A Cross‐Sectional Study

ABSTRACTObjectiveTo explore the impact of psychological and social factors on mother‐infant bonding in women with gestational diabetes mellitus (GDM) living in the United Kingdom.DesignA cross‐sectional online survey study conducted between November 2022 and January 2023 administered to women who self‐reported current or past (within the previous 1 year) GDM.MethodsThe survey comprised demographic and validated self‐report measures for depression, anxiety, eating disorders, perceived social support, pregnancy and birth experience, and breastfeeding. Mother‐infant bonding was measures using the Maternal Antenatal Attachment Scale for women who were currently pregnant with GDM (antenatal) and the Maternal Postnatal Attachment Scale for women with past GDM (postnatal).ResultsN = 149 women (n = 37 antenatal, and n = 112 postnatal) completed the survey. Higher anxiety and depression symptoms and managing GDM using metformin and insulin were associated with poorer mother‐infant bonding for women in both antenatal and postnatal periods. Higher social support was associated with higher mother‐infant bonding scores in women in both the antenatal and postnatal period.ConclusionThe experience of GDM may be amplifying the known risk factors for impaired mother‐infant bonding. Targeted psychological support for women with GDM may be necessary to ensure that their emotional well‐being is addressed as part of comprehensive perinatal care.

A IMPORTÂNCIA DOS CURATIVOS ESPECIAIS EM FERIDAS DE DÍFICIL CICATRIZAÇÃO EM PACIENTES DE UMA CLÍNICA EM VITÓRIA DA CONQUISTA– BA

Wounds that are difficult to heal are those associated with diseases such as DM, SAH, leprosy, neoplasm, neurological and vascular problems, and others. Special dressings are suitable for the treatment of these injuries and, therefore, appropriate care is recommended. This research aims to: evaluate the relationship between the evolution of the healing process and the use of special dressings. This is a cross-sectional, quantitative and exploratory field research conducted in a clinic that specializes in wound prevention and treatment. The study included adults aged 60 to 70 years (50%), with lower limb injury (91.7%) over 1 year (58.3%), pathogenic history of Diabetes Mellitus and Systemic Arterial Hypertension (58.3%). %), adequate nutrition (91.7%), move independently (66.7%), diabetic foot and chronic wound (58.3%), deep wound involvement (83.3%), injured tissue granulated (75%), wounds with exudates and fibrosis (58.3%), moderate (50%) and mild (50%) pain, wound skin / edema (66.7%), macerated (91, 7%) and desquamative (66.7%). The lesions contain serous (41.7%), turbid (41.7%) and moderate (66.7%) exudates and characteristic odor (58.3%). The treatment is done with calcium alginate (66.7%), dressing up to 2 days (58.3%), with evolution in its entirety (100%). In view of the above, it is necessary to use these types of special covers to treat chronic injuries, but also the importance of comprehensive patient care, including the means of prevention, monitoring and treatment of existing co morbidities in order to obtain expected results.

Effects of Short-Term Treatment with α-Lipoic Acid on Neuropathic Pain and Biomarkers of DNA Damage in Patients with Diabetes Mellitus

Background/Objectives: Diabetes mellitus (DM) is a complex and heterogenous disease classified as a group of metabolic disorders characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both. It leads to various complications, some of which are macrovascular or microvascular complications, like diabetic polyneuropathy (DPN), having a profound impact on patients’ quality of life. Oxidative stress (OS) is one of the significant mechanisms in the development and progression of DPN. Thus, targeting OS pathways by antioxidants, such as α-lipoic acid (ALA), could represent a promising therapeutic strategy for alleviating neuropathic symptoms. The aim of our study was to evaluate whether short-term (from 4 to 9 days) intravenous administration of ALA could cause any measurable improvement in subjects with DM. Methods: Sixteen subjects with DM (six type 1 and ten type 2) and sixteen nondiabetic subjects matched by sex and age were recruited to this study. Only subjects with DM received treatment with ALA (600 mg daily). Pain intensity and biomarkers of DNA damage including plasma concentration of 8-hydroxy-2′-deoxyguanosine (8-OHdG), frequency of micronucleated lymphocytes (MN), and frequency of sister-chromatid exchanges (SCEs), were measured before and after the treatment with ALA. Results: Pain intensity and 8-OHdG levels were significantly lower in DM subjects after the ALA treatment than before the treatment. However, no changes in the frequency of SCEs and MN were observed. Conclusions: Our results show some evidence that even a short-term intravenous treatment with ALA could be beneficial for diabetic subjects, reducing pain intensity and concentration of 8-OHdG in blood plasma.

Subcutaneous Insulin Infusion Versus Multiple Administrations of Insulin Analogs: Is Either Method Associated with Better Quality of Life in Pediatric Patients with Type 1 Diabetes Mellitus?

Objectives − Type 1 Diabetes Mellitus (DM1) requires demanding treatment in order to achieve good metabolic control. Our aim was to assess whether either method of insulin administration (multiple daily administrations of insulin analogues (MDIA) or continuous subcutaneous insulin infusion (CSII)) is associated with better health-related quality of life (HRQoL).Methods − We conducted a cross-sectional study. Patients aged 10-18 years with a disease duration of at least six months were included. HRQoL was assessed by having patients and their caregivers complete the DISABKIDS-37 questionnaire.Results − Of the 40 patients included, 22 (55%) had CSII. There were no statistically significant differences between subscale scores and overall HRQoL between patients or between parents of patients with CSII or MDIA. CSII patients and parents scored better on all subscales and on the total scale, although without statistically significant differences. There were no statistically significant differences in the subscale scores and overall HRQoL reported by the patients and their parents, but there was a strong correlation between the children’s and parents’ scores (R=0.770; P<0.01), which was similar in patients with CSII or MDIA (R=0.735 vs R=0.790).Conclusion − Although we did not identify statistically significant differences, there was a trend towards a better HRQoL associated with the use of CSII, both from the perspective of the adolescents and their parents. This could influence therapeutic choice. Consistency between the assessments of adolescents and their carers was observed. The choice between MDIA and CSII should be based on individual preferences in order to optimize the HRQoL of adolescents with DM1.

Time-Efficacy Relationship of Semaglutide in the Treatment of Type 2 Diabetes Mellitus: A Model-Based Meta-Analysis.

Our objective was to quantify the efficacy of subcutaneous once-weekly semaglutide in treating type 2 diabetes mellitus (T2DM) over time. Based on a literature search of the PubMed, Embase, Cochrane, and Web of Science databases, a modified maximum effect (Emax) model including rebound effects was built using model-based meta-analysis with change from baseline in glycated hemoglobin as the efficacy endpoint. This was combined with the covariate model to form a final model, and then theoretical values of Emax and time to reach 50% of Emax (ET50) were obtained for each dose. Model fit and prediction were assessed using goodness-of-fit plots and visual prediction checking. Emax and ET50 were influenced by the proportion of males and the baseline values, respectively. There was no evidence of a placebo effect with semaglutide. The efficacy of other doses became more significant over time, and a rebound effect was observed after maximum efficacy, at a rate of 0.018. Simulation of the typical efficacy at the different doses yielded a maximum efficacy of -1.58% with 0.5 mg and a maximum efficacy of -1.87% with 1 mg. In addition, the six simulated doses (0, 0.1, 0.2, 0.5, 1, and 2 mg) showed a dose-dependent relationship between dose and efficacy except for 0.4 mg and 0.8 mg. A higher dose would result in greater efficacy and a faster onset of action. The efficacy of semaglutide in glucose control was investigated using the model-based meta-analysis method, which yields new insights into the treatment of T2DM with semaglutide.

Association Between Nontraditional Lipid Profiles and the Risk of Type 2 Diabetes Mellitus in Chinese Adults With Hypertension: Findings From the China Hypertension Registry Study.

The relationship between nontraditional lipid profiles and type 2 diabetes mellitus (T2DM) remains ambiguous within the hypertension population. The objective of this study is to examine the association between nontraditional lipid profiles and T2DM in Chinese adults with hypertension. The current investigation encompassed 13728 participants with hypertension from the China Hypertension Registry Study. Logistic regression analysis and smooth curve fitting were employed to evaluate the association between nontraditional lipid profiles and T2DM. The prevalence of T2DM was found to be 17.8%. In the fully adjusted model, atherogenic index of plasma (AIP) exhibited the highest odds ratios (ORs) for T2DM (OR: 2.71, 95% confidence interval [CI]: 2.26-3.26). Conversely, the fully adjusted ORs (95% CI) for total cholesterol (TC)/high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C)/HDL-C, and non-high-density lipoprotein cholesterol (Non-HDL-C) were 1.33 (1.25-1.41), 1.40 (1.29-1.51), and 1.41 (1.34-1.49), respectively. Additionally, the study demonstrated that AIP had a superior ability to identify T2DM. Subgroup analyses indicated that the relationship between AIP and Non-HDL-C with T2DM was more significant in the lighter weight population. In addition, the association of TC/HDL-C with LDL-C/HDL-C with T2DM was stronger in the lower homocysteine level population. Among the southern Chinese population with hypertension, all nontraditional lipid indices positively correlated with the risk of T2DM. Among these lipid indices, AIP exhibited superior discriminatory power in identifying T2DM compared to TC/HDL-C, LDL-C/HDL-C. Trial Registration: ChiCTR1800017274.